SS-31 is widely utilized in in-vitro and preclinical laboratory research involving mitochondrial bioenergetics, oxidative stress, ATP production, cellular metabolism, ischemia-reperfusion injury, and age-related mitochondrial dysfunction
Common side effects of retatrutide include nausea, vomiting, constipation, fatigue, diarrhea, headaches, and abdominal discomfort
Six months of consistent daily application is the minimum meaningful evaluation window for any follicle-targeting intervention
In two cases, the time between when the product was first available to when the shortage was alleviated is certain: eight days for Technetium Tc-99m Sodium Pertechnetate Generator, and 61 days for the tirzepatide shortage
It is increasingly a clinical necessity